SCHEMBL2160267

SCHEMBL2160267

O=[N+]([O-])c1ccc2ncn(S)c2c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 5/20 0.49
HTT P42858 2/20 0.49
TXNRD1 Q16881 1/20 0.49
TXNRD3 Q86VQ6 1/20 0.49
TXNRD2 Q9NNW7 1/20 0.49
MAPT P10636 2/20 0.47
CYP3A4 P08684 1/20 0.46
NAMPT P43490 1/20 0.46
XDH P47989 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALOX5 P09917 1/20 0.44
PKM P14618 1/20 0.44
PARP1 P09874 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL594361 0.87 ALDH1A1 (0.60) FGFR1L3MBTL1ALDH1A1HTTTXNRD1
SCHEMBL19911399 0.80 FGFR1 (0.60) FGFR1L3MBTL1ALDH1A1HTTTXNRD1
SCHEMBL8337275 0.80 FGFR1 (0.60) FGFR1L3MBTL1ALDH1A1HTTTXNRD1
SCHEMBL8425553 0.80 FGFR1 (0.60) FGFR1L3MBTL1ALDH1A1HTTTXNRD1
SCHEMBL1489409 0.80 L3MBTL1 (0.66) FGFR1L3MBTL1ALDH1A1HTTTXNRD1
Hydrochloric Acid SCHEMBL2422409 0.79 FGFR1 (0.58) FGFR1L3MBTL1ALDH1A1HTTTXNRD1
SCHEMBL19911375 0.78 FGFR1 (0.57) FGFR1L3MBTL1ALDH1A1HTTTXNRD1
SCHEMBL19911374 0.78 FGFR1 (0.57) FGFR1L3MBTL1ALDH1A1HTTTXNRD1
SCHEMBL7036153 0.76 FGFR1 (0.56) FGFR1L3MBTL1ALDH1A1HTTTXNRD1
SCHEMBL19911390 0.76 FGFR1 (0.56) FGFR1L3MBTL1ALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985771-B2 Skin disorders; aging resistance MONSANTO TECHNOLOGY LLC (US) 2011-07-26 US disclosed
EP-1660080-A1 FURANONE DERIVATIVES Galileo Pharmaceuticals, Inc. (US) 2006-05-31 EP disclosed
EP-1478634-A4 FURANONE DERIVATIVES GALILEO PHARMACEUTICALS INC (US) 2006-02-01 EP disclosed
WO-2005016340-A1 FURANONE DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2005-02-24 WO disclosed
EP-1478634-A1 FURANONE DERIVATIVES Galileo Pharmaceuticals, Inc. (US) 2004-11-24 EP disclosed
US-20040029812-A1 Furanone derivatives MONSANTO TECHNOLOGY LLC 2004-02-12 US disclosed
US-6667330-B2 Cytoprotective; neuroinflammation and neurodegenerative disorders; oxidative stress related conditions GALILEO PHARMACEUTICALS, INC. 2003-12-23 US disclosed
US-20030176361-A1 Furanone derivatives MONSANTO TECHNOLOGY LLC 2003-09-18 US disclosed
WO-2003064403-A1 FURANONE DERIVATIVES GALILEO LABORATORIES, INC. (US) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176361-A1 Furanone derivatives HSPA9, HSF1, IL1B FGFR1 1152/4885L3MBTL1 4751/4885ALDH1A1 903/4885
US-20040029812-A1 Furanone derivatives TNF, PPIF, NOX5 FGFR1 129/4885L3MBTL1 4884/4885ALDH1A1 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.